Home Other Building Blocks 1354690-24-6
1354690-24-6,MFCD30470232
Catalog No.:AA01EN2Q

1354690-24-6 | Leniolisib

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
98%
in stock  
$19.00   $14.00
- +
5mg
98%
in stock  
$47.00   $33.00
- +
25mg
98%
in stock  
$119.00   $83.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
Technical Information
Catalog Number:
AA01EN2Q
Chemical Name:
Leniolisib
CAS Number:
1354690-24-6
Molecular Formula:
C21H25F3N6O2
Molecular Weight:
450.4574
MDL Number:
MFCD30470232
SMILES:
CCC(=O)N1CC[C@@H](C1)Nc1ncnc2c1CN(CC2)c1cnc(c(c1)C(F)(F)F)OC
Properties
Computed Properties
 
Complexity:
654  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
1  
Heavy Atom Count:
32  
Hydrogen Bond Acceptor Count:
10  
Hydrogen Bond Donor Count:
1  
Rotatable Bond Count:
5  
XLogP3:
2.5  

Downstream Synthesis Route

[1]Patent:WO2012/4299,2012,A1.Locationinpatent:Page/Pagecolumn145

[2]ACSMedicinalChemistryLetters,2017,vol.8,p.975-980

[1]Patent:WO2012/4299,2012,A1.Locationinpatent:Page/Pagecolumn148-149

[2]Patent:WO2013/1445,2013,A1.Locationinpatent:Page/Pagecolumn62

[3]Patent:WO2013/88404,2013,A1.Locationinpatent:Page/Pagecolumn163

[4]Patent:US2015/342951,2015,A1.Locationinpatent:Paragraph0944

[1]Patent:WO2013/1445,2013,A1

[2]Patent:WO2013/88404,2013,A1

[3]Patent:US2015/342951,2015,A1

[4]Patent:WO2012/4299,2012,A1

[1]Patent:WO2013/1445,2013,A1

[2]Patent:WO2013/88404,2013,A1

[3]Patent:US2015/342951,2015,A1

[4]ACSMedicinalChemistryLetters,2017,vol.8,p.975-980

[5]Patent:WO2012/4299,2012,A1

[1]Patent:WO2012/4299,2012,A1.Locationinpatent:Page/Pagecolumn146-147

[2]Patent:US2015/342951,2015,A1.Locationinpatent:Paragraph0940

Literature

Title: Effective 'activated PI3Kδ syndrome'-targeted therapy with the PI3Kδ inhibitor leniolisib.

Journal: Blood 20171123

Title: Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors.

Journal: ACS medicinal chemistry letters 20170914

Title: Genetic defects in PI3Kδ affect B-cell differentiation and maturation leading to hypogammaglobulineamia and recurrent infections.

Journal: Clinical immunology (Orlando, Fla.) 20170301

Title: Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency.

Journal: Nature immunology 20140101

Title: Rao V, et al. Effective 'Activated PI3Kd Syndrome' -targeted therapy with PI3Kd inhibitor leniolisib. The New England journal of medicine: NEJM. ISSN 0028-4793; 1533-4406

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 1354690-24-6
Tags:1354690-24-6 Molecular Formula|1354690-24-6 MDL|1354690-24-6 SMILES|1354690-24-6 Leniolisib